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Abstract
Background: Mechanistic target of rapamycin (mTOR) pathway is essential for the growth of gastric cancer (GC),
but mTOR inhibitor everolimus was not effective for the treatment of GCs. The Cancer Genome Atlas (TCGA)
researchers reported that most diffuse-type GCs were genomically stable (GS). Pathological analysis suggested that
some diffuse-type GCs developed from intestinal-type GCs.
Methods: We established patient-derived xenograft (PDX) lines from diffuse-type GCs, and searched for drugs that
suppressed their growth. Diffuse-type GCs were classified into subtypes by their gene expression profiles.
Results: mTOR inhibitor temsirolimus strongly suppressed the growth of PDX-derived diffuse-type GC-initiating
cells, which was regulated via Wnt-mTOR axis. These cells were microsatellite unstable (MSI) or chromosomally
unstable (CIN), inconsistent with TCGA report. Diffuse-type GCs in TCGA cohort could be classified into two clusters,
and GS subtype was major in cluster I while CIN and MSI subtypes were predominant in cluster II where PDX-
derived diffuse-type GC cells were included. We estimated that about 9 and 55% of the diffuse-type GCs in cluster II
were responders to mTOR inhibitors and checkpoint inhibitors, respectively, by identifying PIK3CA mutations and
MSI condition in TCGA cohort. These ratios were far greater than those of diffuse-type GCs in cluster I or intestinal-
type GCs. Further analysis suggested that diffuse-type GCs in cluster II developed from intestinal-type GCs while
those in cluster I from normal gastric epithelial cells.
Conclusion: mTOR inhibitors and checkpoint inhibitors might be useful for the treatment of a subset of diffuse-type
GCs which may develop from intestinal-type GCs.
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Background
Gastric cancer (GC) is the fifth most common cancer and
the third leading cause of cancer-related deaths worldwide
with nearly one million new cases every year [1]. GCs are
classified into intestinal and diffuse types [2]. Intestinal-
type GCs are composed of glandular solid cells, while
diffuse-type GCs consist of poorly cohesive cells that tend
to infiltrate the gastric wall. Intestinal-type GCs are more
commonly diagnosed in aged patients, have a male pre-
ponderance, and are strongly associated with gastric mu-
cosal atrophy and intestinal metaplasia, both of which are
induced by chronic Helicobacter pylori infection. In con-
trast, diffuse-type GCs are diagnosed in younger patients,
and occur in both sexes [3], but their mechanism of devel-
opment has not yet been fully understood. Ikeda et al.
found that the ratio of diffuse-type GCs was increased in
advanced GCs compared with that in early ones, and sug-
gested that, in some GCs, the predominant histologic type
may be altered from intestinal- to diffuse-type with pro-
gression of the tumor [4]. Arai et al. reported that micro-
satellite unstable (MSI) GCs were significantly related
with older age, female gender, and predominant papillary
adenocarcinoma and solid-type, poorly differentiated
adenocarcinoma, and they suggested that GC with MSI
may originate from differentiated-type carcinomas [5].
However, further analyses do not appear to have been re-
ported. Histological heterogeneity is often found in GC
tissues, and mixed-type GCs composed of intestinal- and
diffuse-type tissues are found in about 22–25% of cases,
and they exhibit worse prognosis than non-mixed-type
GCs [6, 7]. However, it is not clear how the development
of mixed-type GCs is related to that of other GC types.
Diffuse-type GC cells often exhibit more aggressive char-
acteristics than intestinal-type cells, such as rapid infiltrative
growth accompanied by massive stromal fibrosis. These
diffuse-type GCs are called scirrhous-type GCs, and are as-
sociated with frequent metastasis to lymph nodes and the
peritoneum, which contributes to their poor prognosis [8].
Many GC patients with advanced disease eventually experi-
ence relapse, even after curative surgical resection. Following
progression on first-line platinum- and fluoropyrimidine-
based chemotherapy, prognosis for advanced diffuse-type
GC patients is extremely poor. The poor outcomes suggest
a need for molecularly targeted agents that may confer a
better survival benefit, but only a few targeted therapies have
been developed for such patients [9].
Cancer stem cells, or cancer-initiating cells, are cells that
possess the capacity to self-renew and generate heteroge-
neous neoplastic cell lineages that can reconstitute the can-
cer [10]. Recent research has shown that the stem cell
condition is plastic and reversible in response to the micro-
environment. Thus, eradication of cancer-initiating cells by
targeted therapeutics has not been as easy as was initially
hoped [11]. Clinical trials targeting cancer-initiating cells
are now being conducted to evaluate the efficacy of this ap-
proach in a variety of cancers [12–14]. However, further ef-
forts to explore new and more effective drugs remain
warranted. With a greater understanding of the growth
regulatory mechanisms in GC-initiating cells, we may im-
prove patient selection for biological therapy, and thus fur-
ther enhance outcomes for GC patients.
We previously found that CD49f, a biomarker commonly
found in various stem cells including some cancer stem
cells [15], was a marker of GC-initiating cells in both intes-
tinal- and diffuse-type GCs while CD44+/CD133+ cells
were not always tumorigenic [16]. We also succeeded in
cultivating tumor-initiating cells from patient-derived
xenograft (PDX) lines established using intestinal-type
GCs. These intestinal-type GC-initiating cells strongly
expressed CD49f, and grew to form spheres in primary cul-
ture [16]. However, diffuse-type GC-initiating cells have
not yet been fully characterized. In the present study, we
therefore identified GC-initiating cells in PDX lines estab-
lished from diffuse-type GCs, analyzed their characteristics,
and searched for drugs that suppress their growth. We
found that some molecularly targeted drugs might be use-
ful for the treatment of a subset of diffuse-type GCs.
Methods
Establishment of PDX lines and characterization of PDX
cells by FACS
Methods of establishment of PDX lines and their
characterization with fluorescence activated cell sorting
(FACS) have been described in a previous paper [16].
HGC-18 and -20 lines were used at passage number 1–
4, but HGC-3 at passage number 5–9, because HGC-3
tissues at early passages were exhausted by 2015. Fea-
tures of PDX lines established from intestinal-type GCs
have been described in the previous paper [16]. To de-
tect programmed death-ligand 1 (PD-L1) by FACS,
PE-labelled anti-human CD274 (B7-H1, PD-L1) anti-
body, and PE-labelled mouse IgG2b, κ Isotype control
antibody (both from BioLegend) were used.
Primary culture of PDX cells
PDX tissues were dissociated into single cells as previously
described [16], with some modifications. In the previous
study, we used trypsin-EDTA to dissociate intestinal-type
GC PDX tissues, but in the present study, we first treated
diffuse-type GC PDX tissues with 0.1% collagenase (Wako)
for 30min at 37 °C, followed by 0.05% trypsin-0.53mM
EDTA with 0.01% DNase for 30min at 37 °C, because
diffuse-type GC PDXs contain greater amount of collagen
fibers in them. In the previous study, we used Renal Epi-
thelial Basal Medium (REBM; Lonza) supplemented with
B27 (Invitrogen), epidermal growth factor (EGF), gastrin,
and Y-27632 (all from Wako) to cultivate intestinal-type
GC-initiating cells [16]. In the first part of our experiments
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where we examined effect of anti-tumor drugs on the
growth of diffuse-type GC-initiating cells, we used this
REBM-based medium to compare effect of the drugs on
the growth of intestinal-, diffuse-, and mixed-type GC-initi-
ating cells in culture.
Recently, Bartfeld et al. reported that human non-tumor
gastric epithelial cells grew to form organoids in advanced
Dulbecco’s modified Eagle medium /F12 (ADF; Invitro-
gen)-based medium supplemented with growth factors
[17]. We confirmed their results (Additional file 1: Figure
S1), and found that PDX cells grew much faster in the
ADF-based medium than in the REBM-based medium
(Additional file 1: Figure S2). We thus used the ADF-
based medium supplemented with 10mM HEPES, Gluta-
MAX (all Invitrogen), B27, Primocin (Invivogen), 1 mM
N-acetylcysteine (Sigma-Aldrich), 30 ng/mL EGF, 1 nM
gastrin, and 10 μM Y-27632 as basal medium in the
second part of our experiments where we examined effect
of molecularly targeted drugs on the growth of diffuse-
and intestinal-type GC-initiating cells. For the cultivation
of PDX cells, the basal medium was supplemented with
25% R-spondin1-conditioned medium (CM) and 25%
Wnt3a-CM, which were prepared according to a protocol
by Broutier et al. [18].
The expression of PD-L1 on cultured cells was assessed
by culturing 5 × 105 PDX cells in rat tail collagen-treated
12-well plates for 14 days. To examine effects of chemicals
on the expression of PD-L1, drugs were added on day 9 in
culture so that cells were treated with them for 5 days.
Easily-detached cells were harvested by washing the cells
with a Pasteur pipette, and then attaching cells were disso-
ciated by trypsin-EDTA treatment. In some plates,
easily-detached and attached cells were combined and
they were called “whole cells”. This method was used to
obtain easily-detached, attached, and whole cell fractions
from HGC-3, HGC-20, MKN45, and NUGC-4 cells, and
their cell surface antigen was analyzed by FACS with the
anti-CD274 antibody described above.
Tumorigenicity assay and histological analysis
The method has been described in the previous paper
[16]. Briefly, cultured cells were dissociated into single
cells by trypsin-EDTA treatment, and graded numbers
of cells were suspended in 50 mL CMF-PBS. Cell sus-
pension was mixed with an equal volume of Matrigel
(Corning), and subcutaneously injected into NOD-SCID
mice (Charles River Japan, Yokohama, Japan) on the
dorsal side of each flank. To minimize experimental
variability due to individual differences in recipient mice,
cell populations that were to be compared were injected
on opposite flanks of the same animal. The injected mice
were maintained for up to 6 months, and killed when
tumor diameters reached 10 mm. Tumor tissues were
fixed with 95% ethyl alcohol, embedded in paraffin and
sectioned at 5 µM. Sections were deparaffinized and
hydrated using xylene and ethyl alcohol, and stained
with hematoxylin and eosin, and Alcian blue
(pH2.5)-PAS-hematoxylin.
Culture of established cell lines
MKN45, MKN74, and NUGC-4 human GC cell lines
were obtained from JCRB Cell Bank (Osaka, Japan), and
their quality was assessed by their short tandem repeat
profiles by BEX Co. (Tokyo, Japan). They were main-
tained in Dulbecco’s modified Eagle medium (DMEM;
Wako) (MKN45 and MKN74 cells) or RPMI1640
medium (Wako) (NUGC-4 cells) supplemented with
10% heat-inactivated fetal bovine serum (FBS; Hyclone),
but they were cultured in serum-free media used for the
culture of PDX cells when effect of drugs on their
growth was examined.
Organoid culture of non-tumor gastric epithelial cells
Non-tumor gastric epithelial cells were cultured by using
a method developed by Hans Clevers’ laboratory [17].
Non-tumor gastric tissues were washed with cold Hanks’
buffered saline solution, and fats and connective tissues
were removed. The tissues were cut into pieces of ap-
proximately 1 × 3 mm, thoroughly washed with cold
DMEM supplemented with 10% FBS and penicillin-
streptomycin solution (Wako), and stored in the
medium overnight at 4 °C to remove contaminated mi-
croorganisms. Then, they were thoroughly washed with
CMF-PBS and incubated in chelating solution (distilled
water with 5.6 mM Na2HPO4, 8.0 mM KH2PO4, 96.2
mM NaCl, 1.6 mM KCl, 43.4 mM sucrose, 54.9 mM
D-sorbitol, 0.5 mM DL-dithiothreitol, 2 mM EDTA) for
30 min at room temperature. Epithelial and stromal tis-
sues were separated with the aid of forceps under a dis-
secting microscope. Isolated glands were re-suspended
in DMEM supplemented with 10% FBS, dissociated into
small fragments by pipetting, and mixed with Matrigel,
and seeded on dishes pre-coated with Matrigel. After the
gel was polymerized, the tissues with gel was overlaid
with ADF medium supplemented with 10 mM HEPES,
GlutaMAX. B27, Primocin, 200 ng/ml fibroblast growth
factor-10, 25 ng/ml noggin (all from Peprotech), 2 μM
A-83-01, 10 mM nicotinamide (all from Sigma-Aldrich),
1 mM N-acetylcysteine, 30 ng/ml EGF, 1 nM gastrin,
10 μM Y-27632, 25% R-spondin1-CM, and 25%
Wnt3a-CM. Cultures were kept at 37 °C, and at 5% CO2
in a humidified incubator.
Effect of drugs on the growth of diffuse- and mixed-type
GC-initiating cells in primary culture
The method has been described in the previous paper
[16]. Briefly, HGC-3, − 18 and − 20 PDXs were dissoci-
ated into single cells by collagenase and Trypsin-EDTA
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treatment as described above, and seeded in rat tail
collagen-treated 24-well plates. Effect of anti-tumor drugs
on the growth of PDX cells was examined by seeding
HGC-3, -18, and -20 cells at 50,000 cells per well, and by
seeding MKN45 and NUGC-4 cells at 1000 cells per well,
in 0 .5mL REBM-based medium on day 0, and by adding
0 .5mL media containing × 2 concentrated 5-fluorouracil
(5-FU), doxorubicin, or doxifluridine (all from Wako) on
day 1. 5-FU and doxifluridine were dissolved in dimethyl
sulfoxide (DMSO), while doxorubicin in water. DMSO
(final concentration = 0.1%) was added to each well when
cells were treated with 5-FU or doxifluridine. Cell numbers
were determined after 2 weeks by using (4,5-dimethylthia-
zol-2-yl)-2,5-diphenyltetrazolium bromide (MTT; Dojindo)
as substrate as described previously [16].
Effect of molecularly targeted drugs and signaling in-
hibitors on the growth of HGC-3 and -20 cells was ex-
amined by seeding 105 cells in 0 .5mL ADF-based
medium on day 0, and by adding 0 .5mL medium con-
taining 2x concentrated temsirolimus (Abcam), everoli-
mus (Adooq), PP242 (Adooq), CHIR99021 (Wako), or
FH535 (Sigma-Aldrich) on day 1. DMSO was used as
solvent for the drugs and was used as a control. Cell
number was determined by MTT assay on day 5.
RNA extraction, RNA sequencing, and data processing
Total RNAs were isolated from kelp-like structures (KLSs)
formed by HGC-3, -18, and -20 cells by using RNeasy
Mini Kit (Qiagen) according to the manufacturer’s proto-
col. The sequencing library was prepared and RNA-seq
data were processed as has been reported previously [19].
Quantification of each gene was performed using HTseq-
count utility involved in the HTSeq framework (ver.
0.9.1). To handle expression levels of the genes in the
RNA-seq data, counts per million mapped reads of each
sample were calculated. The counts per million data were
normalized by the quantile method, log2-transformed,
and median-centered across genes and samples. Expres-
sion differences in genes in the RNA-seq data were
considered significant if the fold difference in expression
between two sample groups was ≥3.
To compare the molecular characteristics between
PDXs and other GC samples, a hierarchical clustering
analysis was carried out. For cluster analysis, we ob-
tained public data sets of primary diffuse-type GCs from
TCGA (https://cancergenome.nih.gov/) and those of GC
cell lines from Cancer Cell Line Encyclopedia (CCLE;
https://portals.broadinstitute.org/ccle). Before clustering,
the expression levels of each gene in each data set were
standardized independently, to a mean of zero and a
standard deviation of 1. Then, the data sets of TCGA,
CCLE, and PDX samples were pooled into a whole gene
expression data matrix, which were normalized by quan-
tile normalization method. A hierarchical clustering
algorithm, using the centered correlation coefficient as
the measure of similarity and centroid linkage clustering,
was applied.
Gene set enrichment analysis was carried out to iden-
tify the most significant gene sets associated with the
Kyoto Encyclopedia of Genes and Genome pathway
database, in which the significance of over-represented
gene sets was estimated by Fisher’s exact test. Gene set
enrichment analysis was performed using the DAVID
Bioinformatics Resources (ver. 6.8).
To verify molecular subtypes of GC cells, we generated
four prediction models for Epstein-Barr virus (EBV), MSI,
genomically stable (GS), or chromosomally unstable
(CIN) subtypes using data from TCGA cohort according
to the previous study [20]. Briefly, to select EBV, MSI, GS,
or CIN subtype specific genes, multiple two-class t-tests
were performed for all possible combination of the four
subtypes (P < 0.001 by two sample t-test). Genes having
statistical significance in expression in all three possible
comparisons were selected as subtype-specific genes, re-
vealing 718 genes for the EBV subtype, 499 genes for the
MSI subtype, 1965 genes for the GS subtype, and 241
genes for the CIN subtype. The top 200 genes in each sub-
type were further selected for development of the predic-
tion models. For construction of four subtype prediction
models, we applied a machine learning-based prediction
algorithm using the Bayesian compound covariate predic-
tion method. After construction of the models, RNA-seq
quantification data of three diffuse- and mixed-type
GC-initiating cells were applied into the models and their
molecular subtypes were classified. Subtype prediction
procedure was performed based on the BRB-array tools
(version 4.5.0).
Screening of drugs that suppress the growth of diffuse-
type GC-initiating cells and identification of signaling
pathway that regulates their growth
The SCADS inhibitor kit I and II, kinase inhibitor kit, and
molecularly targeted drug kit (total number of drugs was
386) were kindly provided by the Screening Committee of
Anticancer Drugs (Japan). We regarded drugs “positive”
when the growth of HGC-20 cells was suppressed to less
than 50% of controls by the drug at 1 μM. Experiments
were repeated at least twice, and dose-response relation-
ships were confirmed with positive drugs. We then exam-
ined whether the drugs affected the growth of PDX tissues
in vivo. HGC-3 and -20 PDX tissues were dissociated into
single cells, and tumors were produced on the backs of
nude mice (KSN/Slc, Japan SCL, Japan) by subcutaneously
injecting 2 × 105 cells mixed with Matrigel. After 7 days,
tumor-bearing animals were randomized, and temsiroli-
mus, bortezomib (Adooq), and YM155 (Focus) were intra-
peritoneally administrated at 1–10mg/kg body weight to
the animals twice weekly. After 6–7 weeks when the tumor
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was above 1 cm in diameter, animals were sacrificed and
tumors were recovered to examine their weight. We then
compared effect of mechanistic target of rapamycin
(mTOR) inhibitor analogues including temsirolimus,
everolimus, and PP242 on the growth of HGC-3 and -20
cells in vitro and in vivo, using the method described
above. We also used CHIR99021 and FH535 to identify the
signal transduction system in the PDX cells in culture.
Tissue array analyses
A total of 610 and 372 primary GCs from formalin-fixed
paraffin-embedded tissue microarray samples in Seoul Na-
tional University Hospital and Seoul National University
Bundang Hospital were used for immunohistochemical
analyses of mTOR and PD-L1 expressions, respectively, in
GCs. Expression of phosphorylated-mTOR (p-mTOR) was
examined by using anti-p-mTOR rabbit monoclonal anti-
body (clone 49F9) from Cell Signaling Technology, and
Ventana BenchMark XT automatic immunostainer sys-
tems. We classified tissues into high- and low-expressing
by using a score system where we called a tissue “high”
when more than 40% of the tumor cells were positively
stained, and “low” when less than 40% of the tumor cells
were stained. Kaplan-Meier relationship was examined,
and univariate and multivariate analyses were performed
by using GC tissues obtained.
Expression of PD-L1 was examined by using anti-
PD-L1 antibody (clone E1L3N, rabbit monoclonal; Cell
Signaling Technology) and Ventana BenchMark XT
automatic immunostainer systems. Features of patients
used for the analysis are described in a previous paper
[21]. Membrane staining of PD-L1 on more than 5% of
tumor cells was interpreted as positive. mTOR was
immunohistochemically detected as described above,
and membranous and cytoplasmic staining of mTOR
was evaluated using intensity score: 0 (no tumor cell
staining), 1 (weak), 2 (moderate), and 3 (strong), as de-
scribed in a previous paper [22]. By combining results
obtained with staining for mTOR and PD-L1, we exam-
ined the correlation between mTOR and PD-L1 expres-
sions in diffuse-type GCs, by using Chi-square test.
Mutation analysis
Mutation profiles of primary GCs in TCGA are obtained
from The cBioPortal for Cancer Genomics (http://www.
cbioportal.org/). Mutations and copy number variations
(gain and loss) of PDX cells in 409 cancer-related genes
were analyzed using the Ion Comprehensive Cancer Panel
and Ion Proton sequencer (Thermo Fisher Scientific). A
non-tumor gastric tumor mucosa (5Y26) was used as a
control. Sequencing and data analysis were performed as
described [23].
Western blot analysis
Total protein was extracted using RIPA buffer and was
then electrophoresed on SDS-PAGE. Western blotting
was conducted with mouse monoclonal anti-E-cadherin
(1:500; BD Bioscience), anti-MLH1 (1:500; Pharmingen)
and anti-MSH2 (1:500; Merck) antibodies, as has been
reported [24].
Methylation-specific polymerase chain reaction analysis
Methylation-specific polymerase chain analysis was per-
formed as described previously [24]. The primer sequences
for methylation analyses are shown in a previous paper [25].
MSI analysis and CIN analysis
MSI analysis was performed according to Yamashita et al.
[26], by using BAT25, BAT26, and BAT40 as microsatellite
markers. High frequency MSI (MSI-H) was defined as
MSI in > 30% of the markers examined. Chromosome
number was analyzed according to Fleicher [27].
Statistical analyses
Results were statistically analyzed using the non-parametric
Mann-Whitney’s U test or Student’s t-test. For the analysis
of data in tables, Chi-square test was used. A P values
of < 0.05 were considered statistically significant. Patient
survival was calculated from the date of surgery until
death or the date of last follow-up. Survival was evaluated
by the Kaplan-Meier method, and uni- and multi-variate
survival analyses were performed using the Cox propor-
tional hazard model.
Results
Features of diffuse-type GC PDXs and diffuse-type GC-
initiating cells in primary culture
Schematic diagram of experimental procedures is illus-
trated in Fig. 1a. We established three PDX lines (HGC-3,
-18, and -20) from diffuse-type GCs. Clinicopathological
features of diffuse-type GC patients whose cancers were
used for the establishment of PDX lines are described in
Additional file 2: Table S1. We confirmed that PDX lines
retained histological features of the original tumors
(Fig. 1b-g). Signet ring cells were found in all PDXs. In
HGC-3 and -20 PDX lines, no glandular components were
found, while in HGC-18 PDX line, both diffuse and glan-
dular components always co-existed, indicating that it is a
mixed-type GC (Fig. 1e-g). The HGC-18 PDX line may be
useful to examine how mixed-type GCs are formed.
Cancer-initiating cells have been reported to form
spheres in serum-free conditions, and we confirmed this
in our previous study with intestinal-type GC-initiating
cells [16]. In the present study, we found sphere formation
of HGC-3 and -18 cells in culture, but only rarely in
HGC-20 cells (Fig. 1h-j), indicating that sphere formation
may not be a feature of diffuse-type GC-initiating cells.








Fig. 1 (See legend on next page.)
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When these PDX cells were maintained for weeks in cul-
ture, some cells formed KLSs (Fig. 1k, Additional files 3, 4,
5: Movies S1-S3). Similar KLSs were also found in culture
of MKN45 and NUGC-4 cells established from diffuse-
type GCs (Additional files 6, 7: Movies S4, S5). Thus, KLSs
may be a feature of diffuse-type GC cells in vitro. In the
present study, we used KLS cells for the RNA sequencing
analyses below.
The tumorigenicity of cultured PDX cells was examined
by subcutaneously injecting them into NOD-SCID mice.
We found them to be highly tumorigenic, since 300–3000
cells were enough to induce tumor formation in the mice
(Fig. 1l). Cultured PDX cells strongly expressed BMI1,
CD44, EpCAM, and SOX9 (Additional file 1: Figure S3),
and HGC-3, -18, and -20 cells formed diffuse-, mixed-,
and scirrhous-type tumors, respectively, in mice
(Fig. 1m-o). We thus concluded that PDX cells in primary
culture are GC-initiating cells.
We previously reported that intestinal-type GC-initiat-
ing cells expressed CD49f [16]. We examined whether
diffuse- and mixed-type GC-initiating cells also expressed
it. We found that about 5–25% of dissociated PDX cells
strongly expressed it, and that their ratio increased to 10–
30% in primary culture (Additional file 1: Figure S4). For
intestinal-type cells, the ratio increased 5 to 10 times in
culture, consistent with the idea that only CD49fhigh cells
could grow in culture, but for diffuse- and mixed-type
cells, the increase was less, suggesting that CD49f may
play a minor role in the growth of diffuse- and mixed-type
GC-initiating cells.
Diffuse- and mixed-type GC-initiating cells are more
resistant to anti-tumor drugs than established cell lines
and intestinal-type cells in culture
In our previous study, we found that some intestinal-
type GC-initiating cells were more resistant to anti-
tumor drugs than MKN45 and MKN74 cells, while
others were equally as sensitive [16]. In the present
study, HGC-3, -18 and -20 cells in primary culture were
far more resistant to anti-tumor drugs than MKN45 or
NUGC-4 cells (Additional file 1: Figure S5), suggesting
that diffuse- and mixed-type GC-initiating cells are more
resistant to the drugs than intestinal-type cells. This may
be related to the fact that diffuse- and mixed-type GCs
have a worse prognosis than intestinal-type GCs [6, 7].
Diffuse-type GCs are classified into two clusters by gene
expression profiles
To explore why diffuse- and mixed-type GC-initiating
cells were more resistant to anti-tumor drugs than estab-
lished GC cell lines, we compared gene expression profiles
of HGC-3, -18, and -20 cells and established cell lines
(MKN74, MKN45, and NUGC-4 cells) (Fig. 2a). We
identified 1048 genes that were differentially expressed in
these two groups (P < 0.05 by two sample t-test)
(Additional file 2: Table S2). These genes may be related
to the resistance to anti-tumor drugs, because several drug
resistance-related genes such as solute carrier family genes
were included in the list.
Using this gene list, hierarchical cluster analysis was
performed on primary diffuse-type GCs from TCGA
(n = 61) [28], on GC cell lines from CCLE (n = 38) [29],
and on PDX cells in primary culture (n = 3, present
study). We found that samples could be classified into
two clusters (Fig. 2b), each of which consisted of primary
diffuse-type GCs and established GC cell lines. Primary
diffuse-type GCs and established GC cell lines were well
separated, and HGC-3, -18, and -20 cells in primary cul-
ture were included in cluster II together with primary
diffuse-type GCs, indicating that they retained features
of primary GCs. In the following, diffuse-type GCs in
clusters I and II are referred to as diffuse-type C-I and
C-II GCs, respectively.
Identification of temsirolimus as a potent growth
suppressor of diffuse-type GC-initiating cells
Previously, established cell lines such as NCI-60 panel
were used for drug screening, but in vivo activity in a
specific tumor model did not closely correlate with
activity in the same human cancer patients [30].
Gillet et al. found no correlation between clinical
samples and established cancer cell lines on their
multidrug resistance transcriptome, possibly because
survival genes were up-regulated across all cultured
cancer cell lines evaluated, and all cell lines bore
more resemblance to each other, regardless of the
(See figure on previous page.)
Fig. 1 Schematic diagram of the procedures and features of PDX lines in vivo and in vitro. a Schematic diagram of the experimental procedures.
Tumorigenicity and differentiation potency of PDX cells grown in primary culture were examined to determine whether they were GC-initiating
cells. They were further characterized by gene expression profiles and mutation number analyses. By identifying drugs that suppress their growth,
new targeted therapy for diffuse-type GCs was proposed. b-o Light micrographs showing histological features of (b-d) parental tumors, (e-g)
PDXs, and (m-o) tumors formed by injection of cultured cells. Signet ring cells (red arrows in e, f, m, n) were found in HGC-3 and -18 PDXs and
tumors formed by injection of cultured HGC-3 and -18 cells. Stained with Alcian Blue (pH2.5)-PAS-hematoxylin. h-k Phase contrast micrographs of
h, k HGC-3, i HGC-18, and j HGC-20 cells in primary culture. Spheres (red arrows) were found in culture of HGC-18 and -3 cells. When HGC-3 cells
were cultured for weeks, kelp-like structures were found (k, black arrows) (also see Additional file 3: Movie S1). l Ratio of tumor formation by
injection of cultured cells into NOD-SCID mice. Clinicopathological features of diffuse-type GC patients whose cancers were used for the
establishment of PDX lines are described in Additional file 2: Table S1
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tissue of origin, than to the clinical samples that they
were supposed to model [31]. Thus, it is widely rec-
ognized that new primary tumor models are necessary
for drug development.
Tumor organoid culture systems have recently been
extensively developed, and they are now used for drug
screening [32–34], and for prediction of responses to
chemotherapy [35]. Primary GC organoid biobanks have
a
b
Fig. 2 Diffuse- and mixed-type GCs are classified into two clusters by gene expression profiles. a A heat map of 1048 genes which were
differentially expressed in HGC-20, -3, and -18 GC-initiating cells compared with established cell lines (MKN74, MKN45, and NUGC-4 cells), listed in
Additional file 2: Table S2. b A cluster analysis on the expression of these 1048 genes using primary diffuse-type GCs (n = 61 from TCGA), GC cell
lines (n = 38 from CCLE), and diffuse- and mixed-type GC-initiating cells (n = 3, present study)
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recently been reported [36, 37]. Nanki et al. reported
that diffuse-type GCs formed amorphous solid configura-
tions with a loss of apico-basal polarity [36] while Yan et al.
reported diffuse-type GCs grew as isolated cells or in
loosely cohesive to solid cell clusters without glandular
lumen formation [37]. The diffuse-type GC-initiating cells
in the present study did not form organoids (Add-
itional file 1: Figure S6) when cultured in a condition where
non-tumor gastric epithelial cells formed organoids (Add-
itional file 1: Figure S1), indicating that features of
diffuse-type GC cells differed between laboratories. This
may be caused by the different methods used. To eliminate
overgrowing normal organoids, Nanki et al. selected TP53
mutant, RHO-dysregulated, TGF-β-insensitive, and recep-
tor tyrosine kinase-activated GC cells [36], and Yan et al.
used Nutlin3a to enrich TP53 mutants [37] to establish GC
organoid cultures, but we just cultured cells without selec-
tion because normal gastric epithelial cells were not in-
cluded in PDX. In the present study, HGC-20 cells in
primary culture were used to identify drugs that suppress
the growth of diffuse-type GC-initiating cells because (i) we
confirmed that the cells retained features of primary GCs
(Fig. 2b), (ii) they formed scirrhous-type tumors in
immuno-deficient mice (Fig. 1o), (iii) they grew rapidly in
culture, and (iv) PDXs at early passages were available.
By second-round screenings with 364 chemicals, nine,
three, and three inhibitors were identified from kits I,
III, and IV, respectively, which reproducibly suppressed
cell growth (Additional file 1: Figure S7). The three in-
hibitors from kit IV were bortezomib, temsirolimus, and
YM155. Temsirolimus and bortezomib are used for the
treatment of patients with renal cell carcinoma [38], and
multiple myeloma and mantle cell lymphoma [39], re-
spectively, but they are not used for GC patients. Con-
sidering that it is essential to identify new molecularly
targeted drugs for their treatment, effects of these mo-
lecularly targeted drugs on the growth of diffuse-type
GC-initiating cells were further investigated.
We first examined whether the drugs suppressed the
growth of PDX cells in vivo, and found that only temsir-
olimus significantly suppressed it (Fig. 3a). Thus, the
focus was on temsirolimus and its analogues for their ef-
fects on diffuse-type GC-initiating cells.
Temsirolimus is the best among mTOR inhibitors
examined to suppress the growth of diffuse-type GC-
initiating cells
mTOR, or mammalian target of rapamycin, is a central
regulatory kinase that regulates the production of proteins
involved in key cellular processes such as cell growth, me-
tabolism, and angiogenesis. Suppression of the mTOR
pathway has been reported to inhibit the growth of GC
cells in vitro and delay tumor progression in animal
models [40]. However, the effect of temsirolimus on their
growth has not been examined either in vivo or in vitro.
In previous studies, everolimus, another mTOR inhibitor,
was found not to be effective in improving the overall
survival of advanced GC patients [41, 42], although Park
et al. reported that the drug was satisfactory in a
diffuse-type GC patient with PIK3CA mutation [43].
Therefore, the effects of temsirolimus, everolimus, and
PP242, a second generation mTOR inhibitor [44], on the
growth of diffuse-type GC-initiating cells were evaluated
in primary culture and in vivo.
We found that temsirolimus and everolimus signifi-
cantly suppressed the growth of HGC-3 and -20 cells in
vitro, while PP242 had only a weak effect (Fig. 3b). The
growth-suppressive action of temsirolimus appeared to be
modest, but this was because temsirolimus was not toxic
to the cells. Temsirolimus almost completely suppressed
the growth of HGC-20 cells in culture (Additional file 1:
Figure S8). Temsirolimus significantly suppressed the
growth of HGC-3 and -20 cells in vivo and showed
stronger activity than other mTOR inhibitors (Fig. 3c).
Thus, temsirolimus may be the best among the three
mTOR inhibitors examined in the present study.
p-mTOR expression is a prognostic factor for diffuse-type
GC patients
mTOR is an evolutionarily conserved member of the
phosphoinositol kinase-related kinase family whose
activity is regulated by phosphorylation in response to
insulin or muscle activity [45]. Thus, the relationship
between the expression of p-mTOR and the prognosis
of GC patients was examined immunohistochemically.
p-mTOR was detected in both non-diffuse- and
diffuse-type GC tissues (Fig. 4a and c). Kaplan-Meier
analysis showed that diffuse-type GC patients with
strong p-mTOR expression had a significantly worse
prognosis than those with weak p-mTOR expression
(n = 227; P = 0.044; Fig. 4d), while significant differences
were not found in non-diffuse type GC patients (n =
377; P = 0.485; Fig. 4b). The relationship between
p-mTOR expression and other clinicopathological char-
acteristics of GC cases is summarized in Additional file 2:
Table S3. In diffuse-type GCs, p-mTOR was significantly
(P < 0.044) associated with prognosis on univariate ana-
lysis, but not on multivariate analysis (Additional file 2:
Table S4). In the total GC cohort, p-mTOR was not sig-
nificantly associated with prognosis on either univariate
or multivariate analyses (Additional file 2: Table S5).
These results suggest that mTOR is specifically involved
in the prognosis of diffuse-type GC.
mTOR inhibitors may be useful for the treatment of
diffuse-type GC-initiating cells
We compared the effect of temsirolimus on the growth
of diffuse- and intestinal-type GC-initiating cells in
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primary culture. HGC-20 cells were the most sensitive
among the cells examined to the growth-suppressive
action of temsirolimus. Temsirolimus more strongly
suppressed the growth of diffuse-type GC-initiating
cells than that of intestinal-type cells (Additional file 1:
Figure S9). Considering that diffuse-type GC-initiating
cells were more resistant to anti-tumor drugs than
intestinal-type cells or established GC cell lines
(Additional file 1: Figure S5), these results indicate
that mTOR inhibitors may be useful for the treatment
of diffuse-type GC-initiating cells.
Wnt-mTOR axis is involved in the growth regulation of
diffuse-type GC-initiating cells
We tried to identify upstream signaling components that
activated mTOR. Bartfeld et al. have reported that hu-
man gastric epithelial cells require EGF, noggin,
R-spondin1 and Wnt3a for their growth [17], and our
RNA sequencing analysis showed that the Wnt signaling
pathway was up-regulated in HGC-20 cells (Add-
itional file 1: Figure S10). Thus, we compared effect of
Wnt3a/R-spondin1 on the growth of diffuse-type
GC-initiating cells. Wnt binding to its receptor activates
a linear signal transduction cascade, which culminates in
the stabilization of β-catenin. However, it has recently
become clear that this pathway branches off to trigger a
variety of β-catenin-independent pathways including the
activation of mTORC1 signaling, regulation of the Hippo
effectors YAP and TAZ, and the Wnt-STOP pathway
[46]. Thus, the involvement of specific downstream cas-
cades in the Wnt-induced response was assessed accord-
ing to Acebron and Niehrs [47].
We found that the growth of diffuse-type
GC-initiating cells was significantly stimulated by Wnt3a
and R-spondin1, while that of intestinal-type cells was
not (Additional file 1: Figure S11). CHIR99021, a Wnt
signaling activator, significantly stimulated the growth of
HGC-3 and -20 cells, while it did not stimulate that of
intestinal-type cells (Additional file 1: Figure S12), sug-
gesting that Wnt is specifically involved in the growth
regulation of diffuse-type GC-initiating cells. Moreover,
CHIR99021-induced growth was partly and completely
suppressed by mTOR inhibitor temsirolimus in culture
of HGC-3 and -20 cells, respectively (Additional file 1:
Figure S13). These results suggest that the growth of
diffuse-type GC-initiating cells is regulated by the
Wnt-mTOR axis, but that other signaling cascades may
function in HGC-3 cells.
FH535, a β-catenin signaling inhibitor, did not affect
the growth of HGC-20 cells, but it suppressed that of
HGC-3 cells (Additional file 1: Figure S14), indicating
that the Wnt signaling is β-catenin-independent in
HGC-20 cells, but that it is partly regulated by a
β-catenin-dependent pathway in HGC-3 cells. We con-
cluded that the Wnt-mTOR pathway was active in
diffuse-type GC-initiating cells, but not in intestinal-type
cells. In HGC-3 cells, the Wnt-β-catenin pathway was
also active (Fig. 4e).
Mutation profiles of GCs in TCGA cohort
We compared mutation profiles of diffuse-type C-I and
C-II GCs and intestinal-type GCs in TCGA. We found
that ARID1A, PIK3CA, and BRCA2 were significantly
more frequently mutated in diffuse-type C-II GCs than
in diffuse-type C-I or intestinal-type GCs, while muta-
tions in CDH1 were significantly more frequently found
in diffuse-type C-I GCs (23.5%) than in diffuse-type C-II
(3.7%) or intestinal-type GCs (2.6%) (Fig. 5a and b).
Cho et al. reported that somatic mutations in CDH1
or TGFBR1 were more frequently found in early-onset
diffuse-type GCs [48]. Our results that CDH1 and
TGFBR1 mutations were exclusively found in
diffuse-type C-I GCs (Fig. 5b) suggest that diffuse-type
C-I GCs have features of early-onset diffuse-type GCs.
Consistent with this, we found that patients with
diffuse-type C-I GC were significantly younger than those
with intestinal-type GC in TCGA cohort (Additional file 1:
Figure S15), though we could not find differences between
various GCs on the male-to-female ratio.
ARID1A was shown to recruit mismatch repair protein
MSH2 to chromatin during DNA replication and to pro-
mote mismatch repair. Conversely, ARID1A deficiency
correlated with MSI genomic signature, and increased
mutation load across multiple human cancer types [49].
BRCA1/2 are tumor suppressors involved in pathways
important for regulating DNA damage, and BRCA2 mu-
tations were found to be associated with familial aggre-
gations of not only breast but also of stomach cancers
[50]. Then, the results that ARID1A and BRCA2 were
more frequently mutated in diffuse-type C-II GCs than
in C-I GCs (Fig. 5b) suggest that many mutations may
be induced in the tumor by the loss of function of these
(See figure on previous page.)
Fig. 3 Identification of temsirolimus as a potent growth inhibitor for diffuse-type GC-initiating cells. a Effect of temsirolimus, bortezomib, and
YM155 on the growth of HGC-3 and -20 cells in vivo, compared with controls (DMSO). b Effect of temsirolimus, everolimus, and PP242 on the
growth of HGC-3 and -20 cells in primary culture. c Effect of temsirolimus, everolimus and PP242 on the growth of HGC-3 and -20 cells in vivo,
compared with controls (DMSO). Mean ± SD of three (a, c) and five (b) independent experiments. * P < 0.05, ** P < 0.01 (Student’s t-test
compared with controls (Cont))
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tumor suppressors. Consistent with this, we found that
the expression level of MLH1, which encodes a protein
involved in DNA mismatch repair, was significantly (P <
0.001) reduced in diffuse-type C-II GCs than in C-I GCs
in TCGA cohort (Fig. 5c). We expected that some
diffuse-type C-II GCs might be MSI type with defects in
DNA mismatch repair system.
We found that PIK3CA was more frequently mutated
in diffuse-type C-II GCs than in diffuse-type C-I or
intestinal-type GCs (Fig. 5b). Janku et al. [51] reported
that PIK3CA mutations were detected in 11.5% of pa-
tients with diverse solid tumors, and that the response
rate was significantly higher for patients with PIK3CA
mutations treated with PI3K/AKT/mTOR pathway in-
hibitors than for those without documented mutations
(35% vs 6%). Thus, diffuse-type C-II GCs may be more
responsive to temsirolimus than other GCs.
Mutations and epigenetic gene regulation in PDX cells
We also analyzed mutations and copy number variations
in PDX cells. A mutation and a copy number gain in
PIK3CA were found in HGC-20 and -3 PDXs, respectively
(Additional file 2: Table S6). We found that HGC-20 cells
were more responsive to temsirolimus than HGC-3 cells
(Additional file 1: Figure S9). This may be related to that
PIK3CA was mutated in HGC-20 cells.
Mutations in ARID1A were found in HGC-20 and -3
PDXs, and mutations in CDH1 and TP53 were found
only in HGC-3 PDX (Additional file 2: Table S6). Con-
sistent with this, Western blot analysis showed that
E-cadherin was expressed in HGC-18 and -20 cells, but
not in HGC-3 cells (Fig. 5d).
MLH1 and MSH2 were not expressed in HGC-20 and
-18 cells, respectively (Fig. 5d). Methylation-specific
polymerase chain reaction analysis showed that MLH1
promoter was methylated in HGC-20 cells, while it was
not methylated in HGC-3 and -18 cells (Fig. 5e), indicat-
ing that MLH1 is epigenetically silenced in HGC-20
cells. A frameshift mutation in MSH2 was found in
HGC-18 cells (Additional file 2: Table S6), which may
result in the loss of its expression. These results are con-
sistent with the results that ARID1A and BRCA2 were
more frequently mutated (Fig. 5b), and expression of
MLH1 was suppressed in diffuse-type C-II GCs in
TCGA cohort (Fig. 5c), because PDX cells were classified
into diffuse-type C-II GCs (Fig. 2b). These results also indi-
cate that expression of DNA mismatch repair proteins are
suppressed by genetic and/or epigenetic mechanisms dur-
ing the carcinogenesis process of diffuse-type C-II GCs.
HGC-3, -18, and -20 cells retain features of MSI or CIN
subtypes
In a previous study by TCGA researchers, GCs were
classified into EBV, MSI, GS, or CIN subtypes [28], and
the clinical significance of these GC subtypes has been
reported [20]. We therefore attempted to identify the
molecular subtypes of HGC-3, -18, and -20 cells using
TCGA dataset. To construct the precise prediction
model, a Bayesian compound covariate prediction-based
classification algorithm was developed with the
RNA-sequencing data of the cells in primary culture,
and the accuracy of subtype prediction was estimated
(Additional file 1: Figure S16). When the data of the
cells were applied to the MSI or CIN subtype predictors,
all three samples were predicted as MSI (> 93.3%) or
CIN (> 90.7%) subtypes. On the other hand, when the
EBV or GS subtype prediction model were applied to
the cells, all samples were not classified into EBV or GS
subtypes with at least 99% probability (Additional file 1:
Figure S16e). These results indicate that HGC-3, -18,
and -20 cells had shared molecular characteristics of
MSI or CIN subtypes.
HGC-18 and -20 cells are MSI-H, and HGC-3 cells are CIN
Tumor mutation burden can be accurately assessed by
comprehensive genomic profiling assay targeting ~ 1Mb
of coding genome [52]. Numbers of mutated genes in
HGC-3, -18, and -20 cells were estimated to be about
1244, 1569, and 1717, respectively, using data obtained
with the Ion Comprehensive Cancer Panel. The muta-
tion numbers/Mb were similar between PDX cells and
MSI subtypes in TCGA cohort, and their numbers were
far greater than those of CIN, EBV, and GS subtypes
(See figure on previous page.)
Fig. 4 Phosphorylated mTOR expression is a prognostic marker for diffuse-type GC patients, and Wnt-mTOR axis is involved in the growth
regulation of diffuse-type GC-initiating cells. a, c Representative immunohistochemical micrographs of phosphorylated mTOR expressions in
primary intestinal-type (a) and diffuse-type (c) GC tissues. b, d Kaplan-Meier analyses of overall survival for non-diffuse-type (b) and diffuse-type
(d) GC patients with phosphorylated mTOR expression. Diffuse-type GC patients with strong phosphorylated mTOR expression (solid red line) had
a significant poorer outcome than those with weak phosphorylated mTOR expression (dotted blue line) (P = 0.044), while no significant
differences were found between the two in non-diffuse type GC patients. e Wnt-mTOR axis is involved in the growth regulation of diffuse-type
GC-initiating cells. Results on effects of temsirolimus, Wnt3a, R-spondin-1, CHIR99021, and FH535 on the growth of diffuse- and intestinal-type GC-
initiating cells in primary culture, shown in Additional file 1: Figure S9, and Figures S11 to S14 are summarized. Significant growth stimulation is
shown by upward arrows, while significant growth suppression by downward arrows, respectively (no significant changes by horizontal arrows).
Strong (more than 151%) growth stimulations are shown by purple, and strong (less than 66%) and weak (67–100%) growth suppressions are
shown by blue and light blue, respectively (no significant changes by light gray)
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(Fig. 5f ). These results suggest that PDX cells have a fea-
ture of MSI subtype.
HGC-3, -18 and -20 cells were tested for microsatellite
status, as described previously [26]. We found allelic
shifts in the three microsatellites in the panel in both
HGC-18 and -20 cells, but not in HGC-3 cells
(Additional file 1: Figure S17). Chromosome number
analysis showed that aneuploid cells were often found in
HGC-3 cells in primary culture (Additional file 1: Figure
S18), indicating that they are chromosome unstable.
Thus, we concluded that HGC-18 and -20 cells were
MSI-H, and HGC-3 cells were CIN, consistent with the re-
sults obtained with the prediction model (Additional file 1:
Figure S16e). Usually CIN GCs have a small number of
mutations, but HGC-3 cells had many (Fig. 5f). Ben-David
et al. reported rapid accumulation of copy number
alterations during PDX passages [53]. Thus, HGC-3
may have many mutations because we used HGC-3
cells at later passages.
Diffuse-type GCs in cluster II may develop from intestinal-
type GCs while diffuse-type GCs in cluster I from normal
gastric epithelial cells
We found in the present study that expression of DNA
mismatch repair proteins was suppressed in diffuse-type
C-II GCs, and that PDX cells were MSI or CIN. These
results are not consistent with TCGA report that GS
subtype is enriched (73%), and MSI and CIN subtypes
are minor in diffuse-type GCs [28]. We checked TCGA
dataset, and found that classification of GCs has been
changed greatly after their paper was published in 2014.
Forty-four cases were removed from diffuse-type GCs,
21 cases were changed from non-diffuse- to diffuse-type
GCs, and 21 new diffuse-type GC cases were added.
Subtypes of newly added GC cases are not described in
TCGA. At present, 42 diffuse-type GC cases are avail-
able for subtype analysis in TCGA, composed of 17 CIN,
12 GS, 7 MSI, and 6 EBV cases. We examined how four
TCGA subtypes were included in diffuse-type C-I and
C-II GCs. We found that GS and MSI subtypes were
exclusively included in diffuse-type C-I and C-II GCs,
respectively (Fig. 6a), and that the distribution of four
subtypes was significantly (P < 0.001) different between
two clusters. Then, our results are consistent with
TCGA subtype classification. We examined the distribu-
tion of four subtypes in intestinal-type GCs, and found
that the CIN and MSI subtypes were predominant in
intestinal-type GCs, similar to diffuse-type C-II GCs, but
their distribution was significantly (P < 0.001) different
from that of C-I GCs (Fig. 6a).
Data on the number of mutations in primary GCs are
available in TCGA. We compared mutation numbers of
diffuse-type C-I and C-II GCs, and found that those of
diffuse-type C-I GCs (mean = 88, range = 0~358, n = 34)
were significantly (p < 0.001) smaller than those of
diffuse-type C-II GCs (mean = 748, range = 61~3651,
n = 27) in TCGA cohort (Fig. 6b). In addition, the muta-
tion numbers of intestinal-type GCs (mean = 504, range
= 52~5923, n = 76) were similar to those of diffuse-type
C-II GCs, and they were significantly (p < 0.001) greater
than those of diffuse-type C-I GCs (Fig. 6b).
The ratio of four subtypes and the ratio of GCs with
various mutation numbers are summarized in Fig. 6c.
Both ratios were significantly different between
diffuse-type C-I and C-II GCs, and between diffuse-type
C-I and intestinal-type GCs, but both were very similar
between diffuse-type C-II GCs and intestinal-type GCs.
Considering that histologic type was often altered from
intestinal- to diffuse-type with progression of the tumor
[4], and that more than 20% of GCs were mixed-type
composed of intestinal- and diffuse-type GCs [6, 7], we
speculated that diffuse-type GCs were composed of two
populations with distinct developmental pathways; some
diffuse-type C-II GCs may develop from intestinal-type
GCs while diffuse-type C-I GCs from normal gastric
epithelial cells (Fig. 6c).
PD-L1 is expressed by some diffuse-type GCs and is
regulated by mTOR and cell-cell interaction
In the present study, we found that diffuse-type C-II
GC-initiating cells including HGC-3 and -20 cells had
features of MSI or CIN subtypes with many mutations
(Fig. 5f, Additional file 1: Figure S16e). We and others
have reported that MSI GC cells express PD-L1 [54].
(See figure on previous page.)
Fig. 5 Features of mutations in primary GCs in TCGA cohort and PDX cells. a Overview of mutations in diffuse-type GCs in clusters I and II, and
intestinal-type GCs in TCGA cohort. Top 15 most frequently mutated genes are shown. b Mutation frequencies of the top 15 genes in diffuse-
type GCs in clusters I and II, and intestinal-type GCs in TCGA cohort. * P < 0.05, ** P < 0.01 by Chi-square test between two populations. In the
case of PIK3CA, mutation frequency in diffuse-type GCs in cluster II (7/27) was significantly greater than that in intestinal-type GCs (7/76; P =
0.029), or than that in non-diffuse-type GCs in cluster II (diffuse-type GCs in cluster I + intestinal-type GCs; 11/110; P = 0.028). In the case of CDH1,
mutation frequency in diffuse-type GCs in cluster I (8/34) was significantly greater than that in intestinal-type GCs (2/76; P < 0.001), or than that in
diffuse-type GCs in cluster II (1/27; P = 0.030). c Expression of MLH1 in diffuse-type GCs in cluster I and II in TCGA cohort. *** P < 0.001 by two
sample t-test. d Western blot analysis of CDH1, MLH1, and MSH2 in HGC-3, − 18, and − 20 PDXs. GAPDH was used as a loading control. e
Methylation-specific polymerase chain reaction analysis of MLH1 promoter region in HGC-3, − 18, and − 20 PDXs. PCR products recognizing
methylated (lanes M) and unmethylated (lanes U) CpG sites were loaded in 2.5% agarose gels. f Mutation numbers/Mb in HGC-3, − 18, and − 20
cells, and in CIN, MSI, EBV, and GS subtype GCs in TCGA cohort
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Expression of PD-L1 has been reported to be associated
with poor prognosis [55], and programmed death-1
/PD-L1 pathway is now considered an important target
for the treatment of GCs [56]. Moreover, several re-
searchers have reported that expression of PD-L1 is
regulated by mTOR in several tumors [57]. We thus
examined whether diffuse-type GCs express PD-L1 and
whether their expression is regulated by mTOR.
We found that most intestinal-type GC cells expressed
PD-L1 homogenously, while diffuse-type GC cells
expressed it heterogeneously (Fig. 7a). We compared
PD-L1 expression levels in diffuse-type C-I and C-II
GCs in TCGA cohort, and we found that PD-L1 was
expressed by GCs in both clusters (Additional file 1: Fig-
ure S19). We could not find significant differences be-
tween them though strong PD-L1 expression (> 1) was
found only in diffuse-type C-II GCs. Tissue array ana-
lysis showed that about 24% (89/372) of diffuse-type
GCs expressed PD-L1 (Fig. 7b), consistent with our pre-
vious report. This indicates that some diffuse-type C-II
GCs express PD-L1 strongly. A significant correlation
was found between mTOR and PD-L1 expressions
(Fig. 7b), suggesting that mTOR is involved in the regu-
lation of PD-L1 in diffuse-type GCs.
FACS analysis showed that about 3–7% of HGC-3 and
-20 cells expressed PD-L1 strongly, and PD-L1 expres-
sion was suppressed by temsirolimus in HGC-3 cells,
but not in HGC-20 cells (Additional file 1: Figure S20).
We found that the ratio of PD-L1-positive cells in
HGC-20 cells was decreased by washing. Further analysis
showed that PD-L1-positive cells were enriched in the
easily-detached cell fraction (about 15% of total cells) in
HGC-20 cells, but this was not found in HGC-3 cells
(Fig. 7c). PD-L1-positive cells were also enriched in
the easily-detached cell fraction in MKN45 cells
(Additional file 1: Figure S21). As stated previously,
diffuse-type GC-initiating cells formed KLSs when main-
tained for weeks in culture (Fig. 1k, Additional files 3, 4,
5, 6, 7: Movies S1-S5), and KLS-forming cells were in-
cluded in the easily-detached cell fraction. This indicates
that KLS-forming cells express PD-L1 strongly, and that
PD-L1 expression is regulated by cell-cell interactions in
these cells. It has been repeatedly reported that
PD-L1-expressing cells are more resistant to chemother-
apy [58, 59]. Then, KLS-forming PD-L1-expressing
HGC-20 cells may be more resistant to temsirolimus
than attached HGC-20 cells or HGC-3 cells. If the
hypothesis is right, it may be natural that KLS-forming
HGC-20 cells were more resistant to temsirolimus than
HGC-3 cells on the expression of PD-L1 (Additional file 1:
Figure S20).
Considering that PD-L1 overexpression is significantly
related to lymph-node invasion and poor prognosis in
GC patients [55], KLS-forming cells may be an import-
ant target for the development of new therapies against
diffuse-type GCs.
Patients with diffuse-type GCs in cluster II may be
responders to immune checkpoint inhibitors
In the present study, we found that MSI GCs were ex-
clusively included in diffuse-type C-II GCs in TCGA co-
hort (Fig. 6a). It is well established that tumor mutation
burden is strongly correlated with response to therapy
with immune checkpoint inhibitors [60]. Kim et al. re-
cently reported that in metastatic GCs, strong responses
to programmed death-1 inhibition were found in all
cases with MSI and EBV subtype GCs, while responses
were found only in 5 and 12% of cases with CIN and GS
subtype GCs, respectively, by using TCGA subtype clas-
sification [61]. We combined their results with our ana-
lysis shown in Fig. 6a to estimate the ratio of responders
to checkpoint inhibitors in GC patients. We found that
about 21, 55, and 29% of patients with diffuse-type C-I,
C-II, and intestinal-type GCs, respectively, may be re-
sponders to the immunotherapy (Additional file 1:
Figure S22). This indicates that the immune checkpoint
inhibitors may be useful for the treatment of diffuse-type
C-II GCs, but may not good for C-I GCs.
mTOR inhibitors and checkpoint inhibitors may be useful
for the treatment of a subset of diffuse-type GC patients
As shown in Fig. 5b, about 11, 26, and 10.5% of
diffuse-type C-I, C-II, and intestinal-type GCs exhibited
PIK3CA mutations in TCGA cohort, and the overall re-
sponsive rate was reported 35% for cancer patients with
PIK3CA mutations treated with PI3K/AKT/mTOR path-
way inhibitors [51]. By combining these results, we esti-
mated that about 4, 9, and 4% of the respective GCs
may be responders to mTOR inhibitors. PIK3CA muta-
tions were frequently found in MSI GCs [62]. Thus, re-
sponders to mTOR inhibitors may also be responders to
immune checkpoint inhibitors. In TCGA cohort, we
found that all GCs with PIK3CA mutations were MSI or
EBV subtypes in diffuse-type C-I (3/3), C-II (6/6), and
(See figure on previous page.)
Fig. 6 A hypothesis on the relationship between diffuse-type GCs in clusters I and II, and intestinal-type GCs in TCGA cohort. a Distribution of
CIN, MSI, EBV, and GS subtypes in diffuse-type GCs in clusters I and II, and intestinal-type GCs in TCGA cohort. *** P < 0.001 (Chi-square test
between two populations). b Distribution of GC cells with various mutation numbers in diffuse-type GCs in clusters I and II, and intestinal-type
GCs in TCGA cohort. *** P < 0.001 (Chi-square test between two populations). c A hypothesis on the development of diffuse-type GCs in clusters I
and II, and intestinal-type GCs from normal gastric epithelial cells





Fig. 7 (See legend on next page.)
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intestinal-type GCs (5/5). This is consistent with previ-
ous reports that PIK3CA mutations are significantly
more frequently found in MSI and EBV subtype GCs
[28, 62–64]. Our results also indicates that responders to
mTOR inhibitors are also responders to immune check-
point inhibitors. We thus estimated that about 4, 9, and
4% of patients with respective GCs are responders to
both inhibitors (Fig. 7d). We concluded that both inhibi-
tors may be useful for the treatment of a subset of
diffuse-type GC patients.
Discussion
In the present study, we established PDX lines from
diffuse-type GCs, and found that the features of
diffuse-type and mixed-type GC-initiating cells were dif-
ferent from those of intestinal-type cells. We also found
that HGC-20 cells formed scirrhous-type tumors (Fig. 1).
There are many papers on the identification of GC stem
cells [16, 65–68], but to the best of our knowledge, the
formation of scirrhous-type tumors has not been re-
ported when cultured GC-initiating cells were implanted
into immuno-deficient animals. HGC-20 cells may thus
be useful to analyze how scirrhous-type tumors are
formed and to identify drugs that regulate their growth.
In the present study, we found that all three diffuse-type
PDX lines examined were MSI or CIN subtypes, incon-
sistent with TCGA report. It remains to be examined
whether mTOR inhibitors are useful for the treatment of
diffuse-type GCs with other phenotypes. More experi-
ments are needed to examine it with more PDX lines.
Integrative gastric subtyping studies have been re-
ported from several groups, [28, 69, 70], but diffuse-type
GCs have not been classified into subtypes, except re-
cent papers where diffuse-type GCs were classified into
early-onset and late-onset cancers [48], and they were
classified into three types based on proteome analysis
[71]. In the present study, we classified diffuse-type GCs
into two subtypes by hierarchical cluster analysis, and
we obtained strong evidence that diffuse-type C-II GCs
develop from intestinal-type GCs, and diffuse-type C-I
GCs from normal gastric epithelial cells (Fig. 6c), by mu-
tation profile, subtype analysis, and mutation number
analysis. Our results are consistent with those of Cho et
al. [48] that mutations in CDH1 and TGFBR1 were
exclusively found in early-onset diffuse-type GCs, and
indicate that early-onset diffuse-type GCs may develop
from normal gastric epithelial cells. We speculate that
some late-onset diffuse-type GCs may be formed via
intestinal-type GCs. This may be the first report suggest-
ing that some diffuse-type GCs may develop from
intestinal-type GCs, though this idea has long been sug-
gested by histological analysis [4]. We found in this study
that expression of DNA mismatch repair proteins was
suppressed by genetic and/or epigenetic mechanisms in
diffuse-type C-II GCs. This may be a cause why MSI GCs
were exclusively found in this cluster. Further analyses are
needed to clarify why such changes are induced in GCs
during the development and progression of tumors.
By screening drugs that suppress the growth of
diffuse-type GC-initiating cells, we identified mTOR in-
hibitor temsirolimus as a potentially useful drug. This is
consistent with previous reports that mTOR plays an
important role in the growth regulation of GCs [22, 40,
72, 73]. In a previous study, mTOR inhibitor everolimus
was effective for a subset of diffuse-type GC patients
[43], though it was not effective for overall GC patients
[41, 42]. We found PIK3CA mutations more frequently
in diffuse-type C-II GCs (Fig. 5b), indicating that a sub-
set of diffuse-type GCs may be responders to mTOR in-
hibitors. In the present study, temsirolimus was superior
to everolimus in suppressing the growth of diffuse-type
GC-initiating cells in vivo. Both temsirolimus and evero-
limus selectively inhibit mTOR signaling with similar
molecular mechanisms, but with distinct clinical profiles
[72]. It remains to be determined whether temsirolimus
is useful for the treatment of diffuse-type GC patients.
In the present study, we found that expression of
p-mTOR was significantly correlated with clinical aggres-
siveness and worse prognosis in diffuse-type GC patients,
but such relationship was not found in non-diffuse-type
GC patients (Fig. 4b, d). By analyzing the behavior of PDX
cells in primary culture, we found that the Wnt-mTOR
pathway was strongly involved in the growth regulation of
diffuse-type GC-initiating cells (Fig. 4e). This may be the
first report suggesting that mTOR functions differently
between intestinal- and diffuse-type GC-initiating cells.
Carneiro et al. [74] reported that β-catenin was not
found in the in situ carcinomas of E-cadherin
(See figure on previous page.)
Fig. 7 PD-L1 expression in GCs, and estimation of responders to immune checkpoint inhibitors and mTOR inhibitors in patients with various GCs.
a Light micrographs showing PD-L1 expressions in intestinal- and diffuse-type GCs. An area shown by a square in the diffuse-type GC is enlarged
on the right. b The relationship between PD-L1 and mTOR expressions in diffuse-type GCs. A significant difference was found between PD-L1-
positive and -negative patients on the expression of mTOR. *** P < 0.001 by Chi-square test between two populations. c The ratio of PD-L1-
positive cells in whole (attached + easily-detached), attached, and easily-detached cell fractions in HGC-3 and -20 cells. Percentages of PD-L1-
positive cells in the rectangle in the left figures were determined, and compared. Mean ± SD of five independent experiments. * P < 0.05 by two
sample t-test. d Estimation of responders to immune checkpoint inhibitors and mTOR inhibitors in patients with various GCs. Since all PIK3CA
mutated GCs were EBV or MSI subtypes in TCGA cohort, and all patients with EBV or MSI subtype GC were responders to checkpoint inhibitors,
all responders to mTOR inhibitors were responders to checkpoint inhibitors
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mutation carriers with diffuse-type GC, and we previ-
ously found that poorly differentiated carcinoma cells
were β-catenin-negative in a mouse diffuse-type GC
model [75]. Together, these observations suggest that
the growth of diffuse-type GC is regulated by a
β-catenin-independent pathway in both humans and
mice. In contrast, nuclear accumulation of β-catenin was
specifically found in intestinal-type GC from early clinical
stages [76], and growth of intestinal-type GC seems to be
regulated by β-catenin-dependent pathway. Frequent
somatic mutation of the APC and loss of heterozygosity
on chromosome 5q, where the APC is located, have been
frequently detected in intestinal-type GC but not in
diffuse-type GC [77, 78], and somatic mutations of the
β-catenin gene is exclusively detected in intestinal-type
GC [79]. Our results are consistent with these previ-
ous reports, and suggest that Wnt-mTOR axis may
play an essential role in the development of some
diffuse-type GC.
Diffuse-type GCs have been considered non-responders
to the checkpoint inhibitors because GS subtypes were re-
ported to be major in them [28]. In the present study, we
found that GS and MSI subtypes were exclusively included
in diffuse-type C-I and C-II GCs, respectively (Fig. 6a). By
combining results that the ratio of responders to immune
checkpoint inhibitors was significantly associated with
TCGA subtypes [61], we estimated that more than 50% of
patients with diffuse-type C-II GC were responders to the
immunotherapy (Fig. 7d). We hope that our research will
be useful for the development of targeted therapies against
diffuse-type GC.
Conclusions
Previous studies suggested that mTOR inhibitors and
checkpoint inhibitors were not effective for the treat-
ment of diffuse-type GCs. Diffuse-type GCs could be
classified into two clusters with different developmental
pathways. Importantly, we obtained evidence in this
study that these inhibitors may be useful for the treat-
ment of a subset of diffuse-type GC.
Additional files
Additional file 1: Figure S1. Organoid formation by non-tumor gastric
epithelial cells. Phase contrast micrographs of the cells on days 7, 9, 14,
and 18 (a scratch with an arrow indicates that the same organoid was
photographed), and light micrographs showing an organoid consisted of
gastric epithelial cells with various degrees of differentiation. Alcian blue
(pH2.5)-PAS-hematoxylin. Figure S2. Growth of GC-initiating cells in
REBM-based medium (R-medium) and in ADF-based medium (A-
medium). Mean ± SD of five independent experiments. **, P < 0.01 by
Student’s t-test compared with cell numbers in the A-medium. Figure
S3. Expression of stem cell marker genes in HGC cells. Figure S4.
Changes in the ratio of CD49fhigh cells in culture. Significant increases in
the ratio of CD49fhigh cells were found in culture of intestinal-type (HGC-
1, -2, and -4) cells. In culture of diffuse- and mixed-type (HGC-3, − 18, and
− 20) cells, the ratio was significantly increased only in HGC-20 cells.
Mean ± SD of five independent experiments. *, P < 0.05; **, P < 0.01 by
Student’s t-test between before and after cultivation. Figure S5. HGC-3,
-18, and -20 PDX cells, and MKN45 and NUGC-4 cells were treated with
various concentrations of 5-fluorouracil (5-FU), doxorubicin and doxifluri-
dine in REBM-based medium, and cell numbers were determined on day
14 by MTT assay. Mean ± SD of five independent experiments. *, P < 0.05;
**, P < 0.01 by Student’s t-test compared with MKN45 cells (pink asterisks),
and with NUGC-4 cells (blue asterisks) at corresponding drug concentra-
tions. Figure S6. Phase contrast micrographs of HGC-3 and -20 cells in
Matrigel, on day 14 and on day 19, respectively, in culture. Figure S7.
Identification of drugs that suppress the growth of HGC-20 cells in pri-
mary culture. Figure S8. HGC-20 cells were seeded on day 0, drugs were
added on day 1, and cell numbers were determined by MTT assay on
day 5. If a drug completely suppresses the cell growth without toxic ef-
fect, the cell number on day 5 should be equal to that on day 1. Temsiro-
limus at 3 μM (3000 nM) completely suppressed the growth of HGC-20
cells but was not toxic to the cells because the cell number on day 5
was nearly equal to that on day 1. In contrast, bortezomib at 30 nM not
only completely inhibited their growth but also was toxic to the cells be-
cause the cell number was decreased to almost zero on day 5. Mean ±
SD of five independent experiments. *, P < 0.05; **, P < 0.01 by Student’s
t-test compared with controls (Cont). Figure S9. Effect of temsirolimus
on the growth of diffuse- and intestinal-type GC-initiating cells in primary
culture. Mean ± SD of 5 independent experiments. *, P < 0.05; **, P < 0.01
by Student’s t-test compared with controls (Cont; black asterisks), with
HGC-3 (blue asterisks), and with HGC-20 cells (pink asterisks) at corre-
sponding drug concentrations. Figure S10. RNA sequencing analysis of
HGC-20-specific gene set, showing that Wnt-signaling pathway (shown
by red square) is enriched in it. Figure S11. Effect of Wnt3a- and R-
spondin1-CM (+CM) on the growth of diffuse- and intestinal-type GC-
initiating cells in primary culture. Mean ± SD of five independent experi-
ments. **, P < 0.01 by Student’s t-test compared with cell numbers in
basal medium without CM (basal). Figure S12. Effect of CHIR99021 on
the growth of diffuse- and intestinal-type GC-initiating cells in primary
culture. Mean ± SD of five independent experiments. *, P < 0.05; **, P <
0.01 by Student’s t-test compared with controls (Cont; black asterisks),
with HGC-3 (blue asterisks), and with HGC-20 cells (pink asterisks) at cor-
responding drug concentrations. Figure S13. Effect of temsirolimus on
the CHIR99021 (2 μM)-induced growth of diffuse- and intestinal-type GC-
initiating cells in primary culture. Mean ± SD of five independent experi-
ments. *, P < 0.05; **, P < 0.01 by Student’s t-test compared with controls
(Cont; black asterisks) and with HGC-20 cells (pink asterisks) at corre-
sponding drug concentrations. Figure S14. Effect of FH535 on the
growth of diffuse- and intestinal-type GC-initiating cells in primary culture.
Mean ± SD of five independent experiments. *, P < 0.05; **, P < 0.01 by
Student’s t-test compared with controls (Cont). Figure S15. Features of
GC patients in TCGA cohort. a Patients with intestinal-type GCs were sig-
nificantly older than those with diffuse-type GCs in cluster I. *, P < 0.05 by
Student’s t-test. b There was no difference between patients with intes-
tinal- or diffuse-type GCs on the ratio of male to females. Figure S16.
Prediction of molecular subtype of diffuse- and mixed-type GC-initiating
cells using TCGA data set. a A heat map of gene expression patterns in
EBV, MSI, GS and CIN subtypes in TCGA samples and diffuse- and mixed-
type GC-initiating cells (HGC-20, -3, and -18 cells). b Schematic diagram of
TCGA subtype prediction model. A decision tree approach was employed
for categorizing patients in test cohorts into the four subtypes of GCs. c
The performance of a Bayesian compound covariate prediction classifiers
during cross-validation in TCGA dataset. d The Bayesian probability of
each signature was plotted for sensitivity and specificity. e Results of sub-
type prediction. Figure S17. MSI chromatogram for the microsatellites
BAT25, BAT26, and BAT40. DNAs from HGC-18 and -20 cells exhibited al-
lelic shifts for these three microsatellites compared with DNAs from non-
tumor gastric epithelial cells, while no allelic shift was found with DNAs
from HGC-3 cells. Figure S18. Chromosome number analysis of HGC-3
cells in primary culture. Figure S19. Expression of PD-L1 in diffuse-type
GCs in clusters I and II in TCGA cohort. Strong PD-L1 expression (> 1) was
found only in diffuse-type GCs in cluster II, but statistical significance was
not observed between the two clusters. P = 0.1 by two sample t-test.
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Figure S20. Effect of temsirolimus (TEM) on the ratio of PD-L1-positive
cells in HGC-3 and -20 cells. Percentages of PD-L1-positive cells in the
rectangle in the left figures were determined, and compared. Mean ± SD
of at least 5 independent experiments. *, P < 0.05 by two sample t-test.
Figure S21. PD-L1-positive cells were enriched in easily-detached cell
fraction in MKN45 cells. Percentages of PD-L1-positive cells in the rect-
angle in the left figures were determined, and compared. In NUGC-4 cells
which expressed PD-L1 very weakly, significant difference was not found
between cell fractions. Mean ± SD of five independent experiments. *,
P < 0.05 by two sample t-test. Figure S22. Estimation of responders to
immune checkpoint inhibitors in patients with various GCs. Ratios of GC
subtypes in each cluster were obtained from Fig. 6a, and ratio of re-
sponders in each subtype was obtained from Kim et al. [61]. “Estimated
ratio of responders” was calculated by multiplying “Ratio of GC subtypes”
and “Ratio of responders in subtypes”. The ratio of responders was esti-
mated by adding “Estimated ratios of responders”. (PDF 3804 kb)
Additional file 2: Table S1. Clinicopathological features of diffuse-type
GC patients whose cancers were used to establish PDX lines. Table S2.
Differentially expressed 1048 genes in diffuse- and mixed-type GC-
initiating cells compared with established cell lines. Table S3. Clinico-
pathological features of 610 GC cases used to prepare tissue array ana-
lysis. p-mTOR expression was significantly associated with venous
invasion (P = 0.045) and perineural invasion (P = 0.011) in total cases, and
perineural invasion in non-diffuse carcinomas (P = 0.027). P values were
determined by Pearson’s chi-square test. The Spearman rank correlation
analysis was used for pT and pTMN stages. Table S4. Univariate and
multivariate survival analyses of diffuse-type GC (227 cases). p-mTOR was
significantly associated with prognosis in univariate analysis, but it was
not significantly associated with prognosis in multivariate analysis. P
values were determined by Pearson’s chi-square test. The Spearman rank
correlation analysis was used for pT and pTMN stages. Table S5.
Univariate and multivariate survival analyses of total gastric carcinomas
(610 cases). p-mTOR was not significantly associated with prognosis in
univariate or multivariate analyses. P values were determined by
Pearson’s chi-square test. The Spearman rank correlation analysis was
used for pT and pTMN stages. Table S6. Candidate driver gene
mutations and copy number variations in PDX cells. Please refer to
https://www.ncbi.nlm.nih.gov/clinvar/variation/12582/ for pathogenic
(#1), https://www.ncbi.nlm.nih.gov/clinvar/variation/24832/ for patho-
genic (#2), https://www.ncbi.nlm.nih.gov/clinvar/variation/12580 for
pathogenic (#3), and https://www.ncbi.nlm.nih.gov/clinvar/variation/
39706/ for pathogenic (#4). (PDF 406 kb)
Additional file 3: Movie S1. Kelp-like structures found in culture of
HGC-3 cells. Please refer to Fig. 1k for scale bar. (MP4 673 kb)
Additional file 4: Movie S2. Kelp-like structures found in culture of
HGC-18 cells. Please refer to Fig. 1k for scale bar. (MP4 587 kb)
Additional file 5: Movie S3. Kelp-like structures found in culture of
HGC-20 cells. Please refer to Fig. 1k for scale bar. (MP4 1121 kb)
Additional file 6: Movie S4. Kelp-like structures found in culture of
MKN45 cells. Please refer to Fig. 1k for scale bar. (MP4 1130 kb)
Additional file 7: Movie S5. Kelp-like structures found in culture of
NUGC-4 cells. Please refer to Fig. 1k for scale bar. (MP4 1057 kb)
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